Sit Less, Interact and Move More (SLIMM) 2 Study

What Was Tested

This registered phase 2 trial tested Semaglutide.

It had three arms (groups): SLIMM + Standard RT + Placebo (placebo comparator), SLIMM + Guided RT + Placebo (active comparator) and SLIMM + Guided RT + Semaglutide (experimental).

SLIMM intervention for 3 months, followed by a 9-month intervention of SLIMM, standard-of-care resistance training and oral placebo.

SLIMM intervention for 3 months, followed by a 9-month intervention of SLIMM, guided resistance training and oral placebo.

SLIMM intervention for 3 months, followed by a 9-month intervention of SLIMM, guided resistance training and oral semaglutide.

The registry classes the interventions as behavioral and drug.

Who Took Part

Enrollment: 156 planned participants were the target.

It was open to people of any sex aged from 20 years with no upper age limit.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Able to perform resistance training. Access to compatible "smartphone" or device (i.e., Android, Kindle or Apple with internet connectivity or mobile network), desktop or laptop.

The full record lists 3 inclusion and 19 exclusion criteria; among the exclusions: history of gastroparesis or paralytic ileus; at baseline, if sedentary time is 25 min/hr or less, measured by accelerometer; previous bariatric surgery.

How the Study Was Run

The set-up was randomized, parallel-group and quadruple-blind.

Random assignment meant chance, not the researchers, decided who got Semaglutide and who got the comparison, which limits bias.

The Semaglutide group and the comparison group ran side by side rather than switching.

Blinding on both sides kept the participants and researchers unaware of who received Semaglutide.

Those kept unaware of assignments: participant, care provider, investigator and outcomes assessor.

It started in 2021-12-01 with completion listed for 2026-12-31.

It ran at 2 sites in United States (2).

Its stated primary purpose is treatment.

What Was Measured

Primary outcome: Average Change in Sedentary Duration at Months 8, 10 and 12 from Randomization (time frame: Randomization to 12 Months).

It also tracked 4 secondary outcomes, for example Average Change in Steps per Day at Months 8, 10 and 12 from Randomization, Average Change in Stepping Duration at Months 8, 10 and 12 from Randomization, Average Change in Six-Minute Walk at Months 6 and 12 from Randomization and Average Change in Body Fat % at Months 6 and 12 from Randomization.

What This Means in Plain Language

Put simply, this is a phase 2, randomized trial of Semaglutide in 156 people.

It is still recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Semaglutide compound page, all human trials.